Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Clinical Research, Diseases, Myeloid Malignancies, Study Population, Human, Minimal Residual Disease
The goal is to create a portfolio of rationally designed treatment substudies onto which patients sequentially enroll over their treatment journey. As patients transition to higher tiers with increasingly lower remaining tumor burden, the focus will be to target residual disease more precisely.
Methods: Newly diagnosed patients are enrolled onto the Master Screening and Reassessment Protocol (MSRP) for baseline clinical and laboratory evaluation. Specimens are sent to the Molecular Diagnostics Network (MDNet) with a 72-hour turn-around for patient assignment to an initial treatment substudy via an integrated informatics system developed by the NCI Precision Medicine Analysis and Coordination Center (PMACC). Assignments will be based on algorithms adjusted for prevalence of co-mutations to enhance accrual of rare molecular subsets to specific targeted treatment trials.
As shown in figure 1, there are 4 tiers and 5 clinical baskets. Tier-1 is for initial therapy grouped by MDS, younger AML, and older AML. These are typically randomized phase 2 studies testing sensitivity to novel drug combinations with measurable residual disease (MRD) assessment conducted centrally by MDNet. Subsequent therapy occurs in higher tiers. These assignments are made by MDNet/PMACC based on prior treatment substudy outcome. Flow cytometry and duplex sequencing will be employed in Tier-4 clinical trials that will target residual disease. Statistical designs will evaluate the clinical utility of the assays and biomarkers to determine if targeting residual disease confers clinical benefit.
Planned activation is quarter 4 of 2022 with the MSPRP, 2-young adult tier-1 studies and 1 tier-2 study. These are testing combinations of azacitidine, venetoclax, CPX351, 7+3 for ELN defined high risk AML, standard risk AML, and in tier-2 the ability to “erase” residual disease after tier-1 treatment.
Additional studies in development include agents for mutant TP53, KIT, FLT-3, NPM1, IDH 1/2, higher and lower-risk MDS and a study for reduced intensity transplant and maintenance to include efforts for diverse populations. Launch for these studies is planned for mid 2023. Tier-4 studies to target KIT, IDH, FLT3 and others are in discussion.
Discussion: MyeloMATCH is the largest focused investment of infrastructure and researchers ever coordinated by the US Network Groups and NCI that follows patients from diagnosis thorough all treatment in a single disease area. The charge is to rapidly advance therapeutics in myeloid malignancies. MyeloMATCH is designed to efficiently screen and assign patients to precision treatment trials of promising therapeutic combinations. By using early endpoints to identify large activity signals, myeloMATCH will generate data with promising findings for definitive study. The clinical and laboratory data can be interrogated across the initiative to generate hypotheses for additional focused testing. Participants receiving their treatment journey through myeloMATCH will contribute to a unique clinically annotated database with specimens for “omics” serially collected from pre-treatment and through follow up. This will provide a national resource for understanding drug sensitivity and resistance, as well as clonal evolution. In this manner, myeloMATCH aims to reduce the time and investment in failed phase 3 studies, and instead aims to provide high-quality randomized trial data that will enhance selection of phase 3 priorities. We believe this new paradigm for the collaborative conduct of clinical trials may provide meaningful advances for patients with AML and MDS, mentor investigators, and accelerate drug development. Updates and specific treatment-trial designs will be discussed at the meeting.
Disclosures: Othus: Merck: Consultancy; Celgene: Consultancy; Biosight: Consultancy; Glycomimetics: Consultancy; Daiichi Sankyo: Consultancy. Assouline: Genentech/Roche, Astra Zeneca, Novartis, BMS, Jazz, Gilead, Amgen, Beigene, Abbvie, Paladin: Consultancy, Honoraria; Novartis: Research Funding. Atallah: Blueprint: Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Novartis: Consultancy, Research Funding; BMS: Consultancy, Speakers Bureau; Takeda: Research Funding; Servier: Consultancy. Hourigan: Sellas: Research Funding; The Foundation of the NIH AML MRD Biomarkers Consortium: Research Funding; Archer Diagnostics: Other; MissionBio: Other; Qiagen: Other; TwinStrand Biosciences: Other. Luger: Syros, Agios, Daiichi Sankyo, Jazz Pharmaceuticals, Brystol Myers Squibb, Acceleron, Astellas, and Pfizer: Honoraria; Onconova, Celgene, Biosight, Hoffman LaRoche, and Kura: Research Funding. Michaelis: Sierra Oncology: Membership on an entity's Board of Directors or advisory committees, Other: Consulting, Advisory Board Meeting; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees, Other: Consulting, Advisory Board Meeting; Abbvie: Consultancy, Other: Consulting, Advisory Board Meeting; Jazz Pharmaceuticals: Other: Funding for Research Study to my Institution; Incyte Corporation: Consultancy. Odenike: Abbvie; Impact Biomedicines; Celgene; Novartis; BMS; Taiho Pharmaceutical; CTI; Threadwell therapeutics; Bristol-Myers Squibb/Celgene (Inst): Consultancy; Celgene (Inst); Incyte (Inst); Astex Pharmaceuticals (Inst); NS Pharma (Inst); Abbvie (Inst); Janssen Oncology (Inst); OncoTherapy Science (Inst); Agios (Inst); AstraZeneca (Inst); CTI BioPharma Corp (Inst); Kartos Therapeutics (Inst); Aprea AB (Inst): Research Funding. Perales: Vor Biopharma: Honoraria; Orca Bio: Consultancy; Omeros: Consultancy; Novartis: Honoraria; Nektar Therapeutics: Consultancy, Honoraria; VectivBio AG: Honoraria; Cidara Therapeutics: Consultancy; AbbVie: Honoraria; Astellas: Honoraria; MorphoSys: Consultancy, Honoraria; Takeda: Honoraria; Medigene: Consultancy; Servier: Consultancy; Bellicum: Honoraria; Sellas Life Sciences: Consultancy; Miltenyi Biotec: Consultancy, Honoraria; Celgene: Honoraria; Karyopharm: Honoraria; Merck: Consultancy; DSMB: Other; Kite, a Gilead Company: Honoraria, Research Funding; Incyte: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria. Salk: TwinStrand Biosciences Inc: Current Employment, Current equity holder in private company, Other: Founder. Stiff: Incyte: Research Funding; Pfizer: Research Funding; Seagen: Research Funding; Amgen: Research Funding; CRISPR Therapeutics: Consultancy, Honoraria; MorphoSys: Consultancy; Karyopharm: Consultancy, Honoraria, Research Funding; Gamida Cell: Research Funding; Cellectar: Research Funding; Bristol Myers Squibb: Research Funding; Kite, a Gilead Company: Consultancy, Honoraria, Research Funding; Janssen: Research Funding; Macrogenics: Research Funding; Actinium Pharmaceuticals: Research Funding; Gilead: Research Funding. Stock: Syndax: Consultancy, Honoraria; Servier: Honoraria; Pluristem: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Kura Oncology: Honoraria; Kite: Honoraria; Jazz Pharmaceuticals: Honoraria; Amgen: Honoraria; Newave Pharmaceuticals: Consultancy. Stone: Jazz: Consultancy; Janssen: Consultancy; Gemoab: Consultancy; Astellas: Consultancy; Apteva: Consultancy; Arog: Consultancy, Research Funding; BMS: Consultancy; Elevate Bio: Consultancy; Epizyme: Consultancy; Syntrix: Consultancy; OncoNova: Consultancy; Foghorn Therapeutics: Consultancy; Syros: Consultancy; Novartis: Consultancy; Kura Oncology: Consultancy; GSK: Consultancy; Innate: Consultancy; Boston Pharmaceuticals: Consultancy; BerGenBio: Consultancy; Syndax: Consultancy; Takeda: Consultancy; Aprea: Consultancy; Actinium: Consultancy; Abbvie: Consultancy, Research Funding. Zeidan: BMS, AbbVie, Takeda, Novartis, Aprea, Amgen, Otsuka, Gilead, Kura, Loxo Oncology, Geron, Mendus, Tyme: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Erba: Kura Oncology: Consultancy, Research Funding; Forma Therapeutics: Research Funding; Gilead/Forty Seven: Research Funding; PTC therapeutics: Research Funding; ALX Oncology: Research Funding; Pfizer: Consultancy; Daiichi Sankyo: Consultancy, Research Funding; Glycomimetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; ImmunoGen: Consultancy, Research Funding; Incyte: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Research Funding, Speakers Bureau; MacroGenics: Consultancy, Research Funding; Novartis: Consultancy, Research Funding, Speakers Bureau; Covance (Abbvie): Consultancy, Other: Independent Review Committee, Research Funding; Janssen Oncology: Consultancy; Trillium Therapeutics: Consultancy; Takeda: Consultancy; Celgene: Consultancy, Other, Speakers Bureau; Astellas Pharma: Consultancy; Amgen: Consultancy, Research Funding; Agios: Consultancy, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.
OffLabel Disclosure: The drugs discussed will be under IND for investigational use and include anti-CD47 antibodies, inhibitors of KIT, FLT3, IDH 1/2, IRAK4, DNMT, and KMT2A for use in AML and MDS in novel-novel combinations.
See more of: Oral and Poster Abstracts